Evidence map›Paper›PMID 38349459›Full record

ArticleInfection2024

A longitudinal prospective study of active tuberculosis in a Western Europe setting: insights and findings.

Arantxa Romero-Tamarit, Xavier Vallès, María Munar-García, Juan Espinosa-Pereiro, Núria Saborit, Ma Teresa Tortola, Zoran Stojanovic, Sílvia Roure, Adrián Antuori, Pere-Joan Cardona and 16 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03691883 (Design of an Integrative Algorithm for Staging Tuberculosis to Improve Clinical Management.), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03691883 recruitingnot on this map

Design of an Integrative Algorithm for Staging Tuberculosis to Improve Clinical Management.

Typeobservational_patient_registrySponsorFundació Institut Germans Trias i PujolRan2018 to 2026Enrolled200ConditionsTuberculosis
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Nutrition Supplement Improves Treatment Outcome among Adults on the Retreatment Regimen for Tuberculosis; A Two Arm Stepped Wedge Phased Implementation Study.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 9 institutions in 1 country.

Arantxa Romero-TamaritUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Ctra. del Canyet, S/N, 08916, Badalona, Spain.
Xavier VallèsUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Ctra. del Canyet, S/N, 08916, Badalona, Spain.
María Munar-GarcíaUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Ctra. del Canyet, S/N, 08916, Badalona, Spain.
Juan Espinosa-PereiroInfectious Diseases Department, Vall d'Hebrón University Hospital, Universitat Autónoma de Barcelona, Barcelona, Spain.
Núria SaboritInfectious Diseases Department, Vall d'Hebrón University Hospital, Universitat Autónoma de Barcelona, Barcelona, Spain.
Ma Teresa TortolaCIBER of Infectious Disease (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Zoran StojanovicPneumology Department, Hospital Universitari Germans Trias I Pujol, Badalona, Spain.
Sílvia RoureUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Ctra. del Canyet, S/N, 08916, Badalona, Spain.
Adrián AntuoriCIBER Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, 28029, Madrid, Spain.
Pere-Joan CardonaUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Ctra. del Canyet, S/N, 08916, Badalona, Spain.
Antoni Soriano-ArandesPaediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Vall d'Hebron, Barcelona, Spain.
Andrea Martin-NaldaPaediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Vall d'Hebron, Barcelona, Spain.
María EspiauPaediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Vall d'Hebron, Barcelona, Spain.
Maria Luiza de Souza-GalvãoInfectious Diseases Department, Vall d'Hebrón University Hospital, Universitat Autónoma de Barcelona, Barcelona, Spain.
Ma Ángeles JiménezInfectious Diseases Department, Vall d'Hebrón University Hospital, Universitat Autónoma de Barcelona, Barcelona, Spain.
Antoni Noguera-JulianMalalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Servei de Malalties Infeccioses i Patologia Importada, Institut de Recerca Pediàtrica Sant Joan de Déu, 08950, Barcelona, Spain.
Israel MolinaServeis Clínics de Barcelona, Barcelona, Spain.
Xavier CasasServeis Clínics de Barcelona, Barcelona, Spain.
Marisol Domínguez-ÁlvarezHospital del Mar, Barcelona, Spain.
Neus JovéHospital del Mar, Barcelona, Spain.
Nino GogichadzeUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Ctra. del Canyet, S/N, 08916, Badalona, Spain.
Kaori L FonsecaUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Ctra. del Canyet, S/N, 08916, Badalona, Spain.
Lilibeth AriasUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Ctra. del Canyet, S/N, 08916, Badalona, Spain.
Joan-Pau MilletCIBER of Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, 28029, Madrid, Spain.
Adrián Sánchez-MontalváInfectious Diseases Department, Vall d'Hebrón University Hospital, Universitat Autónoma de Barcelona, Barcelona, Spain.
Cristina VilaplanaUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Ctra. del Canyet, S/N, 08916, Badalona, Spain. cvilaplana@igtp.cat.
Instituto de Salud Carlos III · ESUniversitat Autònoma de Barcelona · ESVall d'Hebron Hospital Universitari · ESHospital Del Mar · ESHospital Universitari Germans Trias i Pujol · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESAgencia de Salud Pública de Barcelona · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESDepartament de Salut · ES

Funding

Catalan Government 2017 SGR 500, 2021 SGR 00920European Union's Horizon 2020 research and innovation programme 847762Spanish Government-FEDER Funds CPII18/00031, PI20/01424, PI22/00766, the CIBER Enfermedades Respiratorias (CB06/06/0031)Spanish Society of Pneumology and Thoracic Surgery 169-2022
6 · The paper itself

Abstract

purposeThis study investigates the potential of inflammatory parameters (IP), symptoms, and patient-related outcome measurements as biomarkers of severity and their ability to predict tuberculosis (TB) evolution.

methodsPeople with TB were included prospectively in the Stage-TB study conducted at five clinical sites in Barcelona (Spain) between April 2018 and December 2021. Data on demographics, epidemiology, clinical features, microbiology, and Sanit George Respiratory Questionnaire (SGRQ) and Kessler-10 as Health-Related Quality of Life (HRQoL) were collected at three time points during treatment. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), neutrophil/lymphocyte, and monocyte/lymphocyte ratios (NLR and MLR), complement factors C3, C4, and cH50, clinical and microbiological data, and HRQoL questionnaires were assessed at baseline, 2 months, and 6 months. Their ability to predict sputum culture conversion (SCC) and symptom presence after 2 months of treatment was also analysed.

resultsThe study included 81 adults and 13 children with TB. The CRP, ESR, NLR, and MLR values, as well as the presence of symptoms, decreased significantly over time in both groups. Higher IP levels at baseline were associated with greater bacillary load and persistent symptoms. Clinical severity at baseline predicted a delayed SCC. Kessler-10 improved during follow-up, but self-reported lung impairment (SGRQ) persisted in all individuals after 6 months.

conclusionsIP levels may indicate disease severity, and sustained high levels are linked to lower treatment efficacy. Baseline clinical severity is the best predictor of SCC. Implementing health strategies to evaluate lung function and mental health throughout the disease process may be crucial for individuals with TB.

Indexed as

Quality of LifeTuberculosisAdultChildC-Reactive ProteinHumansLongitudinal StudiesProspective StudiesC-Reactive ProteinBiomarkersClinical monitoringHRQoLInflammatory parametersMycobacterium tuberculosis

Identifiers

PMID38349459
PMCPMC10954962
OpenAlexW4391777496

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.